research Flammulina velutipes polysaccharide boosts the anti-tumor immunity by reversing M1/M2 polarization through TLR4/NF-κB activation
Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.
Search
for
Sort by
Research
960-990 / 1000+ results 
research Peripheral neuropathy associated with tofacitinib use in alopecia universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
research Epidermal γδ T cells, CD8 T cells and macrophages are increased in number in alopecia areata and express BST2 as part of an interferon-driven antiviral gene signature
In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
JAK inhibitors may help improve symptoms in adults with APECED.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research 051 γδ T cells as novel players in alopecia areata pathobiology: Vδ1 + T lymphocytes may recognize “stressed” hair follicle keratinocytes, leading to IFNγ-dependent hair follicle dystrophy and immune privilege collapse
Targeting specific T cells may help treat alopecia areata.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Cyproterone acetate for hirsutism
Cyproterone acetate with estradiol may subjectively improve excessive hair growth in women, but it's not clinically better than other treatments.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Psoriatic Alopecia/Alopecia Areata‐Like Reactions Secondary to Anti‐Tumour Necrosis Factor‐Alpha Therapy
Anti-TNF therapy can cause a rare hair loss condition similar to alopecia areata.
research Comparison Of Single And Double-Spin Platelet- Rich Plasma Therapy For Treating Androgenetic Alopecia In Males: A Double-Blinded Randomized Controlled Trial
Double-spin PRP is more effective for treating male pattern baldness.
research Injectable platelet-rich fibrin promotes proliferation and trichogenic inductivityof dermal papilla cells through activating TGF-β/Smad signaling pathway
Injectable platelet-rich fibrin is better than platelet-rich plasma for promoting hair growth.
research Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients
SARS-CoV-2 may worsen IPF due to shared genes and pathways, suggesting potential drug targets.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Platelet-Rich Plasma Treatment for Endocrine-Induced Alopecia and Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors: A Randomized, Controlled, Pilot Study
PRP may increase hair density but doesn't improve quality of life in breast cancer survivors with hair loss.
research Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation
Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research Advanced Inhibition of Undesired Human Hair Growth by PPARγ Modulation?
GMG-43AC may help reduce unwanted hair growth and treat certain hair loss conditions.